KRAS and colorectal carcinoma: Reminiscent of the patient-derived CRC organoid with an endogenous RAS mutation (P26T), we noticed that the introduction of oncogenic KRAS renders a CRC organoid less sensitive to the afatinib/selumetinib combination therapy (Figure 3C, Video 1).